ProNAi Therapeutics, Inc. (SRRA) Announces Quarterly Earnings Results, Beats Expectations By $0.01 EPS
ProNAi Therapeutics, Inc. (NASDAQ:SRRA) released its earnings results on Thursday. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.01, MarketWatch Earnings reports.
ProNAi Therapeutics (SRRA) traded down 1.4771% during mid-day trading on Friday, reaching $1.5074. The company’s stock had a trading volume of 41,383 shares. The firm has a 50 day moving average price of $1.32 and a 200 day moving average price of $1.35. ProNAi Therapeutics has a 52-week low of $1.10 and a 52-week high of $2.07. The company’s market cap is $78.79 million.
WARNING: “ProNAi Therapeutics, Inc. (SRRA) Announces Quarterly Earnings Results, Beats Expectations By $0.01 EPS” was originally reported by Daily Political and is the property of of Daily Political. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be accessed at https://www.dailypolitical.com/2017/08/11/pronai-therapeutics-inc-srra-announces-quarterly-earnings-results-beats-expectations-by-0-01-eps.html.
Several research firms recently issued reports on SRRA. Zacks Investment Research upgraded ProNAi Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, July 12th. Jefferies Group LLC reiterated a “hold” rating on shares of ProNAi Therapeutics in a report on Thursday, July 27th.
About ProNAi Therapeutics
Sierra Oncology, Inc, formerly ProNAi Therapeutics, Inc, is a clinical-stage drug development company. The Company’s lead drug candidate, SRA737, is orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1), a key cell cycle checkpoint and central regulator of the deoxyribonucleic acid (DNA) Damage Response (DDR) network.
Receive News & Ratings for ProNAi Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProNAi Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.